Market Trends of Oral Cancer Therapy Industry
Targeted Drug Therapy Segment is Expected to Witness Significant Growth Over the Forecast Period
Targeted therapy highlights the treatment modalities of cancer at the molecular level. These therapies are extremely targeted and specific. Targeted therapies have dramatically changed the landscape of treatments for a variety of oral cancers and improved clinical outcomes. Unlike conventional cancer treatment regimens, new agents interfere with the growth and survival of cancer cells by interacting with the specific receptors and intracellular signaling pathways involved in carcinogenesis and cancer progression.
For instance, in July 2023, Rakuten Medical, Inc., suggested that the novel treatment approach of Alluminox treatment using ASP-1929 in combination with anti-PD-1 therapy showed promising early results in patients with locoregional and metastatic head and neck squamous cell carcinoma (HNSCC). Additionally, targeted therapies are more advantageous because of their targeted actions; these drugs affect only cancer cells and do not affect other cells, and targeted drugs often work by blocking cancer cells from multiplying. Thus, the advantages of these targeted drugs, along with new developments, increase the demand for targeted therapies, which is expected to boost the market growth over the forecast period.
The targeting method and the highly effective tumor suppression effect expand the field of vision for the noninvasive diagnosis and treatment of oral cancer. The most important factor is that as the treatment ends, the side effects also go away. Also, because of resistance, targeted therapies work best when used with other therapies or with other treatment cancers such as chemotherapy. The advancement in the treatment option towards targeted therapy has boosted the growth of the segment during the forecast period.
North America is Expected to Dominate the Oral Cancer Market Over the Forecast Period
North America is expected to dominate the market owing to improved infrastructure of the health systems, including better health education and facilities. This has indirectly helped in earlier detection and availability of treatment options. According to the American Cancer Society, the estimated number of oral cancer patients in the United States is about 54,580 new cases in 2023. This shows the high burden of oral cancer in the country which likely increases the demand for oral cancer treatment products and is expected to boost the market growth over the study period in the region.
Most of the key pharmaceutical players have contributed to the market growth of the oral cancer market in North America through product recommendations, and launches. For instance, in November 2023, TerSera Therapeutics LLC stated that the National Comprehensive Cancer Network Head and Neck Cancers Panel recommended the GnRH agonist goserelin for patients with recurrent, unresectable, or metastatic salivary gland tumors who were not eligible for surgery or radiation therapy. These recommendations increase the demand for usage of these drugs in the region which is likely to have a significant impact on the market over the forecast period.
Therefore, owing to the factors such as the high burden of oral cancers and new product recommendations the growth of the market studied is anticipated in the North American region.
